Abstract
Abstract Background: Renal cancer is the 3rd most common cancer of the urinary tract. It peaks at the age of 64 years and appears more common in men than women. Methods: The purpose of this study is to review the potential therapeutic options in metastatic renal cancer. A thorough MEDLINE/PubMed nonsystematic literature review was conducted from 1990 to May of 2023. The terms used for the search were “metastatic” AND “renal cancer” OR “renal cell carcinoma” AND “therapy” OR “treatment” AND “metastasectomy” AND “immunotherapy”. Results: Metastasectomy is advantageous when the metastatic foci are completely excised. When there is no clinical suspicion of any remaining metastatic disease, there is no need for further systemic therapy. Patients at intermediate risk may initiate neoadjuvant systemic therapy with immune-oncology (IO) and IO or tyrosine kinase inhibitor and IO; once the tumor regresses, metastasectomy is performed. Conclusion: In conclusion, there are many modalities for metastatic renal cancer treatment which depend on the prognostic factors of the disease itself.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
